تقرير تحليل حجم السوق العالمية للمواد الحيوية للقلب والأوعية الدموية وحصتها واتجاهاتها – نظرة عامة على الصناعة وتوقعاتها حتى عام 2031

تحليل سوق المواد الحيوية للقلب والأوعية الدموية

يشهد سوق المواد الحيوية للقلب والأوعية الدموية نموًا كبيرًا بسبب الانتشار المتزايد لأمراض القلب والأوعية الدموية والتقدم في المواد الحيوية المستخدمة في الأجهزة الطبية والغرسات. تلعب هذه المواد، التي تشمل المعادن والبوليمرات والسيراميك والمركبات، دورًا حاسمًا في تطوير الأجهزة مثل الدعامات وصمامات القلب وأجهزة تنظيم ضربات القلب والطعوم الوعائية. يتم دفع السوق من خلال الطلب المتزايد على الجراحة الأقل توغلاً وتحسينات في خصائص المواد والحاجة المتزايدة للعلاجات المخصصة في رعاية القلب والأوعية الدموية. تشمل التطورات الأخيرة الابتكارات في البوليمرات القابلة للتحلل البيولوجي واستبدال صمامات القلب، والتي تهدف إلى تحسين نتائج المرضى مع تقليل المضاعفات. يعمل عدد السكان المسنين المتزايد، جنبًا إلى جنب مع التبني المتزايد لتقنيات المواد الحيوية المتقدمة، على دفع نمو السوق بشكل أكبر. بالإضافة إلى ذلك، تعمل الشراكات بين مصنعي الأجهزة الطبية وموردي المواد الحيوية على تعزيز البحث وتطوير المنتجات في هذا المجال، مما يوفر فرص نمو واعدة في سوق المواد الحيوية للقلب والأوعية الدموية.

حجم سوق المواد الحيوية للقلب والأوعية الدموية

تم تقييم حجم سوق المواد الحيوية للقلب والأوعية الدموية العالمية بنحو 13.58 مليار دولار أمريكي في عام 2023 ومن المتوقع أن يصل إلى 22.86 مليار دولار أمريكي بحلول عام 2031، مع معدل نمو سنوي مركب بنسبة 6.72٪ خلال الفترة المتوقعة من 2024 إلى 2031. بالإضافة إلى الرؤى حول سيناريوهات السوق مثل القيمة السوقية ومعدل النمو والتجزئة والتغطية الجغرافية واللاعبين الرئيسيين، فإن تقارير السوق التي أعدتها Data Bridge Market Research تتضمن أيضًا تحليلًا متعمقًا من الخبراء وعلم الأوبئة للمرضى وتحليل خطوط الأنابيب وتحليل الأسعار والإطار التنظيمي.

اتجاهات سوق المواد الحيوية للقلب والأوعية الدموية

"العلاج المتقدم لأمراض القلب والأوعية الدموية"

The cardiovascular biomaterials market is witnessing significant growth, driven by the increasing demand for advanced materials in the treatment of cardiovascular diseases. Innovations in biomaterials, such as bioresorbable stents, and the development of self-healing materials are transforming treatment options. One notable trend is the shift toward minimally invasive procedures, facilitated by the use of advanced biomaterials such as polymers and composites. These materials offer enhanced biocompatibility, reduced risk of rejection, and improved performance. The growing focus on personalized medicine and tailored cardiovascular solutions is further pushing innovation in this market. As a result, cardiovascular biomaterials are becoming essential for developing next-generation medical devices, contributing to better patient outcomes and fueling market growth.

Report Scope and Cardiovascular Biomaterial Market Segmentation

Cardiovascular Biomaterial Market Definition

Cardiovascular biomaterials are specialized materials used in the development of medical devices and implants designed for the treatment of cardiovascular diseases. These materials, which can be natural or synthetic, include metals, polymers, ceramics, and composites. They are used in products such as stents, heart valves, pacemakers, vascular grafts, and other cardiovascular devices. The primary goal of cardiovascular biomaterials is to ensure compatibility with the human body, promote tissue healing, reduce the risk of complications, and improve the performance and longevity of the implanted devices.

Cardiovascular Biomaterial Market Dynamics

Drivers

• Rising Prevalence of Cardiovascular Diseases

The increasing prevalence of heart conditions, such as coronary artery diseases, heart failure, and arrhythmias, is a significant driver of the cardiovascular biomaterials market. As these conditions become more common due to factors such as aging populations, sedentary lifestyles, and unhealthy diets, there is a rising demand for effective treatments, including biomaterial-based implants. These implants, such as stents, heart valves, and pacemakers, help address cardiovascular issues by improving blood flow, stabilizing heart rhythms, and replacing damaged heart valves. The need for these solutions contributes to the growing adoption of advanced biomaterials, accelerating the market's expansion.

• Minimally Invasive Procedures

The growing preference for minimally invasive cardiovascular procedures is a key driver of the cardiovascular biomaterials market. These procedures, which utilize advanced biomaterials such as bioresorbable stents, vascular grafts, and heart valves, offer several benefits over traditional open-heart surgeries, including smaller incisions, reduced risk of infection, and quicker recovery times. Patients experience less trauma, shorter hospital stays, and a faster return to normal activities, contributing to improved overall outcomes. The increasing shift toward these procedures, supported by continuous advancements in biomaterial technology, is driving the demand for innovative solutions, thus fostering market growth.

Opportunities

• Development of Bioresorbable Materials

The rise of bioresorbable stents and scaffolds is a major opportunity in the cardiovascular biomaterials market. These devices offer the advantage of gradually dissolving within the body after serving their purpose, eliminating the need for permanent implants. This reduces the risk of long-term complications such as inflammation, thrombosis, or restenosis that can occur with traditional metallic stents. As the demand for more advanced and patient-friendly solutions increases, bioresorbable biomaterials are gaining traction. Their potential to improve patient outcomes by minimizing the need for further surgeries and reducing healthcare costs drives the demand for these innovative biomaterials, creating significant market growth opportunities.

• Advancements in 3D Printing

The integration of 3D printing technology in creating customized cardiovascular devices presents a significant opportunity for innovation in the biomaterials market. By using 3D printing, manufacturers can design and produce devices that are precisely tailored to a patient's unique anatomy and medical needs. This can lead to improved outcomes, as the devices can be optimized for better fit and function, particularly for complex cases. Customization through 3D printing allows for more personalized treatment, enhancing the patient experience and reducing the likelihood of complications. As the technology advances, it is expected to drive the growth of cardiovascular biomaterials, offering unique, patient-specific solutions.

Restraints/Challenges

• Competition and Market Fragmentation

The cardiovascular biomaterials market is highly competitive, with numerous companies offering similar products such as stents, heart valves, and grafts. This intense competition can lead to price wars, where manufacturers lower their prices to attract customers, ultimately reducing profit margins. Additionally, the presence of multiple players offering comparable solutions makes it challenging to differentiate new technologies. Innovations in materials or design may not always stand out in a crowded marketplace, slowing adoption and hindering companies from gaining a competitive edge. As a result, firms must invest in unique value propositions and effective marketing strategies to overcome these challenges and stand out.

•  High Costs of Advanced Materials

The production of advanced cardiovascular biomaterials, including bioresorbable stents and customized 3D-printed devices, involves high manufacturing costs due to the complexity of the materials and technologies required. These elevated costs can limit accessibility, particularly in developing regions with less advanced healthcare infrastructure. Patients without adequate insurance coverage may also face financial barriers, restricting their ability to afford these cutting-edge treatments. This price disparity between high-cost innovations and more affordable traditional options can slow the widespread adoption of advanced cardiovascular biomaterials, posing a significant restraint to market growth and limiting access to life-saving therapies for many.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Cardiovascular Biomaterial Market Scope

The market is segmented on the basis of type and product. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Natural
• Ceramic
• Metallic
• Polymer

Product

• Catheters
• Stents
• Implantable Cardiac Defibrillators
• Pacemakers
• Sensors
• Heart Valves
• Vascular Grafts
• Guidewires
• Ventricular Assist Devices

 Cardiovascular Biomaterial Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, and product as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to lead the cardiovascular biomaterial market, driven by advancements in medical technology and the high prevalence of cardiovascular diseases. These conditions often lead to severe, irreversible organ damage, creating a strong demand for effective biomaterial treatments. As a result, the region is witnessing increased adoption of cardiovascular biomaterials to address these healthcare challenges.

Asia-Pacific is projected to experience the fastest growth in the cardiovascular biomaterial market from 2024 to 2031. This growth is driven by the rising prevalence of cardiovascular diseases and cardiac-related conditions in the region. The increasing demand for advanced treatment options to address these health challenges is fueling the market's expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Cardiovascular Biomaterial Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Cardiovascular Biomaterial Market Leaders Operating in the Market Are:

• dsm-firmenich (Netherlands)
• Wright Medical Group N.V. (U.S.)
• Zimmer Biomet (U.S.)
• Bayer AG (Germany)
• BASF (Germany)
• CRS Holdings LLC. (U.S.)
• Invibio Ltd. (U.K.)
• Foster Corporation (U.S.)
• CVD Equipment Corporation (U.S.)
• Abbott (U.S.)
• Baxter (U.S.)
• Medtronic (Ireland)
• Johnson & Johnson Private Limited (U.S.)
• Boston Scientific Corporation (U.S.)
• Edwards Lifesciences Corporation (U.S.)
• BD (U.S.)
• Molnlycke Health Care AB (Sweden)
• Smith+Nephew (U.K.)
• Integra LifeSciences Corporation (U.S.)
• Messe-Düsseldorf GmbH (Germany)
• AnteoTech (Australia)
• ANYGEN (South Korea)

Latest Developments in Cardiovascular Biomaterial Market

• في أكتوبر 2023، أعلنت شركة أبوت، الرائدة في مجال التكنولوجيا الطبية، عن استحواذها على شركة Tendyne Holding, Inc. ويعزز هذا الاستحواذ الاستراتيجي محفظة أبوت للقلب البنيوي من خلال دمج علاجات استبدال الصمام التاجي عن طريق القسطرة (TMVR). وتعزز هذه الخطوة قدرة أبوت على تقديم حلول متقدمة لصمام القلب وتوسيع حضورها في سوق القلب البنيوي
• في أغسطس 2023، قدمت شركة Zimmer Biomet نظام Persona Q-Fix Femoral System، وهو تقدم كبير في جراحة استبدال مفصل الورك بالكامل بأقل تدخل جراحي. تم تصميم هذا النظام المبتكر لتعزيز الكفاءة الجراحية ومنح الجراحين سيطرة أفضل من خلال نهج أكثر انسيابية. يمثل الإطلاق تطورًا رئيسيًا في تحسين نتائج المرضى وتبسيط إجراء استبدال مفصل الورك بالكامل بأقل تدخل جراحي.
• في مايو 2023، أعلن قسم الأجهزة الطبية في شركة جونسون آند جونسون عن شراكة مع Cardiovascular Imaging Solutions (CIS) لتطوير وتسويق نظام تصوير داخل الأوعية الدموية من الجيل التالي للتدخلات الوعائية الطرفية. يستفيد التعاون من خبرة CIS في تقنية التصوير المقطعي البصري (OCT) إلى جانب نقاط القوة التي تتمتع بها شركة جونسون آند جونسون في تطوير الأجهزة الطبية وتسويقها. يهدف هذا التحالف إلى تطوير قدرات التصوير وتحسين نتائج المرضى في إجراءات الأوعية الدموية الطرفية
• في أبريل 2023، اندمجت شركة CRS Holdings Inc. وشركة Bioventus LLC لتشكيل كيان واحد تحت اسم Bioventus، مما يمثل إنجازًا مهمًا في سوق المواد الحيوية. ومن المقرر أن يؤدي هذا الاندماج إلى إنشاء شركة عالمية رائدة في مجال حلول الأنسجة الرخوة والعظام، والاستفادة من التآزر في البحث والتطوير والتصنيع والتوزيع. تهدف الشركة الموحدة إلى دفع عجلة الابتكار، وخاصة في قطاع المواد الحيوية لأمراض القلب والأوعية الدموية.
• في فبراير 2023، قدمت شركة Covestro مادة البولي كربونات Makrolon 3638، المصممة لتطبيقات الرعاية الصحية وعلوم الحياة. تم تصميم هذه الدرجة المتينة من البولي كربونات لتحمل الاستخدام اليومي مع الحفاظ على سلامتها البنيوية. يسلط الإطلاق الضوء على التزام شركة Covestro بتوفير مواد عالية الأداء للاستخدامات الطبية والعلمية الحرجة

SKU-64386